Clinical Trials Logo

Clinical Trial Summary

The aims of this study are to: 1. Determine the proportion of participants who are underdosed or overdosed under recommended dosing regimen of escitalopram for the depression treatment (10 mg/day) 2. Determine and quantify clinical benefits of personalized escitalopram dosing regimen based on the escitalopram blood level monitoring 3. Retrospectively estimate whether the information on CYP2C19 genotype is useful in the prediction of escitalopram blood level.


Clinical Trial Description

Escitalopram is an antidepressant extensively metabolized by the polymorphic CYP2C19 enzyme. Based on CYP2C19 genotype, patients can be classified either as: - Normal metabolizers (Normal CYP2C19 enzyme capacity) - Intermediate metabolizers (Decreased CYP2C19 enzyme capacity) - Poor metabolizers (Absent CYP2C19 enzyme capacity) - Ultra rapid metabolizers (Increased CYP2C19 enzyme capacity) Adequate escitalopram exposure is needed to achieve optimal clinical response in the treatment of depression: too low drug plasma levels can lead to the lack of pharmacological effect, whereas too high drug plasma levels increases the incidence of adverse effects. There is evidence that patients with variant CYP2C19 genotypes have abnormal escitalopram exposure and could benefit from escitalopram dose personalization, but precise evidence-based protocol for personalized dosing of escitalopram has not been developed yet. This multicentric observational clinical trial is designed to collect crucial information for the development of such protocol that will be based on drug plasma level monitoring and/or CYP2C19 genotyping. The course of the study will be as follows: Initial Visit (V0): Participant will be enrolled at this point if inclusion criteria are met. Escitalopram therapy will be initiated at the standard dose of 10 mg/day during next 2 weeks, or alternatively, started with 5 mg/day during first week and then increased to 10 mg/day during second week. General and socio-demographic information about the participant will be collected together with the baseline measurements: clinical questionnaires, anthropometric measurements, cardiology assessments, and the blood sample will be taken for biochemical analyses. Mid-Visit (VK): This visit takes place two weeks after the initial visit (V0) when escitalopram blood level is expected to reach the steady state. Blood sample will be taken from the participants at the end of the dose interval (before the morning dose) for the purpose of therapeutic drug monitoring. Plasma escitalopram levels will then be measured before the next visit and an independent clinician will allocate patients into one out of two cohorts based on whether or not escitalopram levels were optimal (25 - 50 ng/ml). If escitalopram levels were outside this interval, independent clinician will adjust the dose; escitalopram level lower than 5 ng/ml indicates noncompliance and results in dropout, level between 5 and 15 ng/ml results in dose increase to 20 mg/day, level between 15 and 25 ng/ml results in dose increase to 15 mg/day, level between 25 and 50 ng/ml results in treatment continuation with 10 mg/day, and level higher than 50 ng/ml results in dose decrease to 5 mg/day. Visit 1 (V1): Visit 1 takes place two weeks after VK and 4 weeks after the initiation of the escitalopram therapy. Without the knowledge of the attending clinician, independent clinician will adjust escitalopram doses accordingly. Attending clinician will then assess the participants using standardized questionnaires, participants will be anthropometrically and cardiologically examined, and blood samples will be taken for the purposes of therapeutic drug monitoring and biochemical analyses. Visit 2 (V2): Visit 2 is the final follow-up visit and it will be performed 4 weeks after the Visit 1 and 8 weeks after the escitalopram initiation. All participants will be assessed for psychometrical, anthropometrical and cardiological parameters, and blood samples will be taken again for the purposes of therapeutic drug monitoring and biochemical analysis. If needed, additional participants, who are already on the stable escitalopram monotherapy, can be enrolled into study starting from VK. In this case, besides the blood sample for the therapeutic drug monitoring, all assessment usually done at initial visit (V0) will be performed during VK. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05210140
Study type Observational
Source University of Belgrade
Contact Marin M Jukic, PhD
Phone +381 11 3951 314
Email marin.jukic@pharmacy.bg.ac.rs
Status Recruiting
Phase
Start date July 16, 2020
Completion date November 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05988333 - Psychoeducational Intervention for Families With a Member Affected by Major Depression N/A
Completed NCT02919501 - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder Phase 2
Completed NCT00976560 - Clinical Study to Test a New Drug to Treat Major Depression Phase 2
Recruiting NCT05518149 - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Phase 3
Not yet recruiting NCT06303076 - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial Phase 4
Not yet recruiting NCT05901571 - Acupuncture and Escitalopram for Treating Major Depression Clinical Study N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Suspended NCT02546024 - Predictors of Treatment Response in Late-onset Major Depressive Disorder N/A
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01152996 - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study Phase 3
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00369343 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women Phase 3
Completed NCT00366652 - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects Phase 3
Completed NCT00384033 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder Phase 3
Completed NCT00149643 - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Phase 2
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4